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Abstract
Pulmonary mucoepidermoid carcinoma (MEC) is a rare malignant neoplasm with the clinical picture mimicking 
infectious aetiologies in most of the patients. Hence, this rare entity poses a great challenge to the pathologist in 
terms of diagnosis and to the oncologist in terms of treatment. This case report aims to look at the clinicopathological 
features of pulmonary MEC, the role of immunohistochemical analysis in diagnosis and choice of chemotherapeutic 
agent. The objective of reporting this case on MEC is not only the rare frequency of this carcinoma but also to 
highlight the importance of adequate immunohistochemical analysis in establishing the diagnosis.
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Mucoepidermoid carcinoma (MEC) of the lung is a 
rare pulmonary cancer that accounts for 0.1–0.2 % 
of lung tumours.[1-3] Main presenting features are of 
cough, fever and haemoptysis.[3] Histological and 
immunohistochemical analysis remain the mainstay in 
establishing diagnosis with radiology providing little 
additional help.[4]
We present a case report on a 25-year-old female 
whose clinical presentation was with cough and 
haemoptysis. Initially, she was diagnosed with poorly 
differentiated squamous cell carcinoma and underwent 
pneumonectomy. Histological review of resected 
specimen showed MEC 4.3 cm, high grade and with a 
pathological stage of pT2aN2. Immunohistochemical 
analysis showed p63 positive, thyroid tissue for 1 (TTF1) 
negative and periodic acid–Schiff–diastase (PASD)/
mucicarmine positive for mucin and was helpful in 
establishing the diagnosis.
Case Report
Our patient, a 25-year-old female with no comorbidities 
and 5 months gravid, presented to pulmonology clinic 
with a history of cough for 3 years and haemoptysis 
for 1 month. Computed tomography (CT) scan from an 
outside facility which showed the right lower lobe mass 
and appearances suggestive of a T2, N2 and Mx primary 
right lower lobe lung tumour.
The patient underwent tumour biopsy at our hospital which 
showed poorly differentiated squamous cell carcinoma. 
Immunohistochemical analysis showed positive p40 and 
negative TTF. Keratinization was absent. After discussion 
in multidisciplinary team conference, pneumonectomy 
was planned.
Histopathology review showed lung parenchyma showing 
an invasive tumour composed of solid nests and sheets. 
The tumour showed two cell populations, predominantly 
comprising epidermoid cells and intermixed mucin 
filled cells with the presence of moderate to marked 
atypia, nuclear pleomorphism and brisk mitotic activity 
[Figure 1].
A diagnosis of MEC was made which was high 
grade 4.3 cm and with lymphovascular invasion. Four of 
nine regional nodes were positive including ipsilateral 
mediastinal/subcarinal node making it a stage of pT2aN2. 
Immunohistochemical analysis showed positive p63 and 
PASD/mucicarmine positive for mucin, whereas TTF1 
was negative. The previous biopsy was also reviewed 
and the final diagnosis of MEC was made on the basis of 
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two cell populations, the absence of keratinization and a 
negative TTF1.
The patient was then seen in medical oncology clinic, 
chemotherapy was planned, but since the patient was 
pregnant, she was first referred to obstetrics for induction 
of labour. She came for chemotherapy after delivery of 
her child. A baseline CT scan was done and chemotherapy 
carboplatin AUC-5 and paclitaxel 175 mg/m2 every 
3 weeks were started. There was an interval of 4.5 months 
between surgery and first chemotherapy cycle. Our patient 
received 6 cycles of carboplatin and paclitaxel without any 
significant toxicity. She remained on active surveillance 
and disease free for up to a year. Her disease relapsed at 
multiple sites, and unfortunately, she could not be given 
second-line chemotherapy in view of her florid disease 
and poor performance score.
Discussion
MEC is defined by the World Health Organisation as 
a tumour comprising mucus secreting, squamous and 
intermediate cells.[1,4] More frequently, it is found in the 
parotid and the submandibular salivary glands.[4] MEC 
equally affects males and females both with the median 
age of presentation at 40 years; however, the range is wide 
from 3 to 78 years.[4,5]
In general, it involves the proximal bronchi, and hence, 
the patient presents typically with symptoms suggestive 
of bronchial obstruction such as cough, haemoptysis, 
wheezing, fever and post-obstructive pneumonia.[3,4]
Chest radiographs may show distal atelectasis or 
pneumonia and rarely help in diagnosis. CT scan generally 
shows non-spherical, smooth polypoidal mass.[5]
Histologically, the tumour can be classified as low grade 
or high grade.[6] Low grade mostly has cystic components 
with mild atypia. High-grade tumours predominantly show 
squamoid and intermediate cell with a small component of 
mucin-secreting cells with high mitotic rate.[7] Making a 
diagnosis of high-grade MEC before surgery is difficult. 
It is the histological findings of the presence of three 
components, mucin secreting, squamous and intermediate 
that help establish the diagnosis of MEC.[4] To distinguish 
MEC from adenosquamous carcinoma is not easy. 
The absence of keratinization and TTF1 negativity is 
suggestive of high-grade MEC.[8]
Surgical resection remains the standard treatment for 
pulmonary MEC. Video-assisted thoracoscopic surgery 
is becoming more common operative approach.[3] In 
low-grade tumours, adjuvant therapy is not indicated.[5]
Prognosis of low-grade MEC is excellent with 5-year 
survival of 95%. In contrast, high-grade MEC carries a 
poor prognosis with most of the patients succumbing to 
disease.[3,6] Lymph node metastasis is the most important 
prognostic factor in pulmonary MEC and imparts a dismal 
outcome. Therefore, surgery alone does not seem to be 
adequate for such patients.[8]
The role of adjuvant chemotherapy and targeted agents 
has only been studied in case reports. Epithelial growth 
receptor (EGFR) mutation is found in 40% of cases of 
pulmonary MEC and gefitinib has shown effectiveness in 
such cases as reported.[9] However, there have also been 
reports of response to tyrosine kinase inhibitors (TKIs) in 
patients with no EGFR mutation which warrants further 
studies.[3,9]
Conclusion
Rare tumours pose a challenge to the pathologist and 
oncologist both in terms of diagnosis and treatment, 
respectively. MEC of the lung is one such entity. Literature 
review is available mainly in the form of case reports, and 
Figure 1: Lung parenchyma showing invasive tumour with 
two cell populations, predominantly epidermoid and mucin-
filled cells
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hence, there are no established chemotherapy protocols. 
The significance of this case report is to highlight the 
importance of histological and immunohistochemical 
analysis in the diagnosis of this infrequent tumour. One 
important aspect that was investigated was the use of 
carboplatin and paclitaxel as chemotherapeutic agents 
and assessment of disease response.
Needless to say, more studies are required to define the 
optimal treatment regimens for initial presentations as 
well as relapsed/refractory disease.
Established facts
• Rare tumour with clinical presentation mimicking 
infectious aetiology.
• Pathology and immunohistochemical analysis are 
essential for diagnosis with radiology having a limited 
role.
• Surgery as the mainstay of treatment in low-
grade MEC.
Novel insights
Role of chemotherapy in high-grade pulmonary MEC. In 
areas like ours, the resources are limited and a number of 
patients have financial restraints which of course mean 
that testing for EGFR mutations, and consequently, the 
use of TKIs is not really a practical option. Therefore, 
we have to rely on chemotherapy in adjuvant settings in 
case of high-grade tumours. The only literature on the 
choice of chemotherapeutic agents in pulmonary MEC 
is in the form of case reports and series. In the case of 
our patient with high-grade MEC, we used carboplatin 
and paclitaxel which provided a disease-free survival 
of 1 year.
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